|
CN107286143A
|
|
Canagliflozin impurity of the drug as well as preparation method and application thereof
|
|
CN104535675A
|
|
Method for determining cumene hydroperoxide impurity
|
|
CN104478715A
|
|
Preparation method of compound
|
|
CN104330488A
|
|
Method applied to detection of suspected genotoxic impurities in dexlansoprazole
|
|
CN104188936A
|
|
Retigabine micro pellet capsule and preparation method thereof
|
|
CN104130091A
|
|
Method for reducing diyne compounds
|
|
CN104130207A
|
|
Acotiamide hydrobromide hydrate and preparation method of crystal form thereof
|
|
CN103992360A
|
|
Reduction method suitable for industrialized production
|
|
CN103638020A
|
|
Novel pharmaceutical composition for treating gout
|
|
CN103508958A
|
|
Novel celecoxib crystal form C and preparation method thereof
|
|
CN103529205A
|
|
Quantitative determination method for titer of recombinant insect baculovirus
|
|
CN103524416A
|
|
Novel crystal form A of celecoxib and preparation method thereof
|
|
CN103360248A
|
|
Synthesis method of laspeyresia pomonella sex pheromone intermediate (2E, 4E)-2,4-hexadienol acetate
|
|
CN104098696A
|
|
Monoclonal antibody resisting vascular endothelial growth factor
|
